Treatment-Resistant Depression Archives

Psychedelic Drug Headed to Pivotal Trial in Treatment-Resistant Depression

Clinical Trials, Major Depressive Disorder (MDD), Psychadelics, R&D, Treatment-Resistant Depression

COMPASS Pathways revealed positive topline results from the mental healthcare firm’s Phase IIB clinical trial on the use of COMP360 psilocybin to address treatment-resistant depression (TRD).

VistaGen’s Antidepressant Fails in Difficult-to-Treat Patients Trial

Antidepressants, Clinical Trials, CNS, Fast Track Designation, FDA, Major Depressive Disorder (MDD), N-methyl-D-aspartate (NMDA) receptor, Nasal Sprays, National Institute of Health, Social Anxiety Disorder, Treatment-Resistant Depression

When major depressive disorder does not respond to at least two different types of antidepressant treatments in a moderate-to-severe depressive episode, it’s reclassified as treatment-resistant depression (TRD). South San Francisco-based VistaGen Therapeutics’ AV-101 failed to meet the primary efficacy endpoints for TRD in a Phase II clinical trial.

J&J’s nasal spray antidepressant wins U.S. approval

Anesthetics, Approvals, Boxed Warning, Elevated Blood Pressure, FDA, FDA/Regulatory, Major Depressive Disorder (MDD), Nasal Sprays, Potential Blockbusters, Treatment-Resistant Depression

The U.S. FDA approved Johnson & Johnson’s nasal spray antidepressant Spravato for people resistant to other treatments, but placed restrictions on use of the drug.